03/09/2026
🧬🌱 Biological Material & CRISPR-Cas9: The Next Licensing Challenge in Agriculture
CRISPR-Cas9 is transforming agricultural innovation—from disease-resistant crops to improved yield and climate resilience.
But behind the science lies an important IP question:
👉 Who can legally license and commercialize biological materials and CRISPR-based technologies when rights pass through multiple layers of licensing?
Secondary licensing can create complex issues around:
🔹 Patent rights and biological material ownership
🔹 Scope of sublicensing rights
🔹 Research vs. commercial use
🔹 Access to CRISPR-Cas9 tools and platforms
🔹 Technology transfer and royalty obligations
🔹 Compliance across different jurisdictions
For agricultural innovators, universities, biotech companies, and technology licensors, carefully structured licensing agreements are becoming just as important as the underlying science.
Learn More: https://www.ipandlegalfilings.com/biological-material-and-crispr-cas9-secondary-licensing-in-agriculture/